Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib versus best supportive care for advanced biliary tract cancer
ChiCTR1900020686Phase 2Not yet recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Best supportive care with Anlotinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR1900020686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020686.